Pablo Legorreta is the Chief Executive Officer of Royalty Pharma PLC Class A, a leading biopharmaceutical investment company. Born and raised in Mexico, Legorreta moved to the United States to pursue higher education, earning a Bachelor's degree in Economics from Universidad Anáhuac and an MBA from The Wharton School at the University of Pennsylvania. His career in finance and healthcare began in the early 1990s when he worked at Lazard Frères & Co., focusing on mergers and acquisitions in the healthcare sector. In 1996, he founded Royalty Pharma, recognizing the potential in investing in royalties from pharmaceutical products. Under Legorreta's leadership, Royalty Pharma has grown into a powerhouse in the biopharmaceutical industry, managing a portfolio of royalties on more than 45 commercial products and 15 development-stage product candidates. His innovative approach to financing drug development has enabled numerous pharmaceutical companies to bring life-saving treatments to market more efficiently. Legorreta's strategic vision and commitment to advancing healthcare have earned him numerous accolades, including being named one of the "100 Most Influential People in Healthcare" by Modern Healthcare. As CEO of Royalty Pharma, Legorreta oversees the company's investment strategy, focusing on identifying and acquiring royalties that offer strong potential returns while also contributing to global health advancements. His leadership has been instrumental in navigating the complex landscape of biopharmaceutical investments, ensuring that Royalty Pharma remains at the forefront of the industry. Legorreta's dedication to improving patient outcomes through innovative financing solutions continues to drive the company's success and impact on the healthcare sector.